Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05393817
Other study ID # KC22OISI0314
Secondary ID
Status Completed
Phase
First received
Last updated
Start date June 8, 2022
Est. completion date October 18, 2023

Study information

Verified date November 2023
Source Seoul St. Mary's Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Caffeine citrate, the first-line agent for apnea of prematurity, enhances diaphragmatic activity. EDI values of neurally adjusted ventilatory assist (NAVA) modes can be used to quantify the diaphragmatic activity triggered by electrical impulse from the respiratory center. This study aims to evaluate the EDI changes following caffeine citrate administration and cessation in preterm infants, and whether such changes are affected by different doses used variably in clinical settings.


Description:

Caffeine citrate has been used as the first-line agent for apnea of prematurity. It works via mechanisms including stimulation of the respiratory center in medulla, increasing sensitivity to carbon dioxide retention, and increment in diaphragmatic activity. The effect of caffeine citrate has been evaluated largely based on parameters concerning clinical symptoms (e.g., decrease in the number of apnea, extubation success, decreased incidence of bronchopulmonary dysplasia) but not quantified parameters of actual diaphragmatic activity. Also, while usual doses of caffeine administration is described in the literature, consensus on the effect of caffeine citrate depending on different dosages has not been established. The current study aims to evaluate effect of caffeine citrate by quantifying the electrical impulses of diaphragmatic activity using EDI values captured from neurally adjusted ventilatory assist (NAVA) mode. Out of preterm infants necessitating invasive or non-invasive ventilators, those who are supported by invasive or non-invasive NAVA would be recruited. EDI changes would be monitored for the following timepoints: at the administration of caffeine citrate loading dose, 1st maintenance dose after loading, and at cessation of caffeine citrate.


Recruitment information / eligibility

Status Completed
Enrollment 14
Est. completion date October 18, 2023
Est. primary completion date October 18, 2023
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Preterm infants born at less than 34 weeks' gestation who are supported by invasive or non-invasive NAVA Exclusion Criteria: - major congenital anomaly, chromosomal or genetic abnormality

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
caffeine citrate
caffeine citrate administration, dosage decided by the the physician on duty, within the range of routine management (5mg/kg/day ~ 20mg/kg/day)

Locations

Country Name City State
Korea, Republic of Seoul St. Mary's Hospital Seoul Seocho-Gu

Sponsors (1)

Lead Sponsor Collaborator
Seoul St. Mary's Hospital

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Other respiratory outcome of caffeine citrate administration (1) duration of invasive mechanical ventilation (days) During neonatal intensive care unit stay up to 48 weeks postmenstrual age (average of 3 months)
Other respiratory outcome of caffeine citrate administration (2) bronchopulmonary dysplasia severity (no/mild/moderate/severe) 36 weeks postmenstrual age or at discharge, whichever comes first
Primary EDI change after caffeine citrate loading dose changes in EDI min and EDI peak values (µV) after the loading dose administration 20 minutes before ~ 20 minutes after loading dose of caffeine citrate
Primary EDI change after caffeine citrate maintenance dose changes in EDI min and EDI peak values (µV) after the 1st maintenance dose 20 minutes before ~ 20 minutes after 1st maintenance dose of caffeine citrate
Primary EDI change after caffeine citrate cessation changes in EDI min and EDI peak values (µV) after caffeine discontinuation 20 minutes before ~ 48 hours after caffeine citrate discontinuation (discontinuation time point definition: 48~96 hours after the last dose of caffeine citrate administration)
Secondary short-term effect of caffeine citrate administration number of apnea and/or bradycardia 24 hours before ~ 24 hours after caffeine citrate administration
See also
  Status Clinical Trial Phase
Completed NCT06038903 - The Turkish Version Of The Brief-Caffeine Expectancy Questionnaire
Completed NCT02900261 - Study on Sodium and Caffeine in Children and Adolescents
Completed NCT03850275 - The Effects of e+Shots Energy Beverage on Mental Energy N/A
Completed NCT01924481 - Effects of a Cocoa Shot on the Human Brain N/A
Completed NCT01330680 - Genetic Determinants of Cardiovascular Response to Coffee Drinking N/A
Completed NCT00184912 - The Effect of Caffeine on Ischemic Preconditioning N/A
Completed NCT03859882 - Protocol PERCAF 2018 N/A
Completed NCT02832401 - The Impact of Caffeine on Cognition in Schizophrenia N/A
Completed NCT04560595 - Remote Guided Caffeine Reduction N/A
Recruiting NCT05503732 - Effects of Energy Drinks on Sleep and Cardiovascular Health N/A
Not yet recruiting NCT05521386 - The Effects of Caffeine on Heart Rate and Heart Rate Variability N/A
Completed NCT06039358 - Effects of Caffeine Ingestion on the Biomechanics of Healthy Young Subjects N/A
Active, not recruiting NCT04547868 - Can Coffee/Caffeine Improve Post-Operative Gastrointestinal Recovery N/A
Completed NCT05559372 - Energy Drink Effects on Performance, Mood, and Cardiovascular Outcomes N/A
Completed NCT01783561 - Early Versus Routine Caffeine Administration in Extremely Preterm Neonates Phase 4
Completed NCT04852315 - Acute Caffeine Ingestion on Futsal Performance N/A
Completed NCT05975489 - Genetics in the Effect of Caffeine on Fat Oxidation N/A
Recruiting NCT03298347 - Caffeine for Preterm Infants With Apnea of Prematurity(AOP) N/A
Completed NCT01435486 - Caffeine Citrate for the Treatment of Apnea Associated With Bronchiolitis in Young Infants N/A
Completed NCT04869176 - Effect of Caffeine on Heart Rate Variability in Newborns N/A